FAST NEWS: HutchMed, AstraZeneca Launch Phase III Trials for Renal Cancer Joint Drug Treatment
The latest: HutchMed (China) Ltd. (0013.HK; HCM.US) announced that it and British drug firm AstraZeneca (AZN.L) have launched phase III global trials for a combination therapy combining the drugs Savolitinib…
Biotech Aspirant Hutchmed Sails Full Steam Toward Hong Kong Homecoming IPO
Company backed by billionaire Li Ka-shing secures cornerstone investors for more than half of its $600 million secondary listing in its home market Key points: • Hutchmed announces new approvals…
RECENT ARTICLES
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK -
NEWS WRAP: Hutchmed sells non-core asset to focus on cancer treatment
0013.HK HCM.US
- Cancer drug maker Genfleet joins Hong Kong IPO influx
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
